CASI Pharmaceuticals, Inc. SEC filings CASIF

CASI Pharmaceuticals, Inc. has 157 filings in SEC EDGAR's recent list, going back to Jan 31, 2023. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 2, 2026. The company's fiscal year ends on December 31.

CASI Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
6-K Current report (foreign issuer) Sep 2, 2026 Sep 2, 2026
6-K Current report (foreign issuer) Aug 14, 2026 Aug 14, 2026
6-K Current report (foreign issuer) Aug 13, 2026 Aug 13, 2026
6-K Current report (foreign issuer) Jul 15, 2026 Jul 15, 2026
6-K Current report (foreign issuer) Jun 29, 2026 Jun 29, 2026
25-NSE Delisting notice Jun 23, 2026 —
6-K Current report (foreign issuer) Jun 2, 2026 Jun 2, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) May 18, 2026 —
20-F Annual report (foreign issuer) May 15, 2026 Dec 31, 2025
D Filing Apr 28, 2026 —
3 Initial insider ownership Apr 23, 2026 Mar 18, 2026
NT 20-F Filing Apr 21, 2026 Dec 31, 2025
3 Initial insider ownership Apr 20, 2026 Mar 18, 2026
6-K Current report (foreign issuer) Apr 20, 2026 Apr 20, 2026
6-K Current report (foreign issuer) Apr 20, 2026 Apr 20, 2026
3 Initial insider ownership Apr 16, 2026 Mar 18, 2026
6-K Current report (foreign issuer) Apr 15, 2026 Apr 15, 2026
3 Initial insider ownership Apr 13, 2026 Mar 18, 2026
3 Initial insider ownership Apr 7, 2026 Mar 18, 2026
3 Initial insider ownership Apr 3, 2026 Mar 18, 2026
3 Initial insider ownership Apr 3, 2026 Mar 18, 2026
3 Initial insider ownership Mar 27, 2026 Mar 18, 2026
3 Initial insider ownership Mar 25, 2026 Mar 18, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Mar 23, 2026 —
3 Initial insider ownership Mar 18, 2026 Mar 18, 2026
3 Initial insider ownership Mar 18, 2026 Mar 18, 2026
6-K Current report (foreign issuer) Mar 3, 2026 Mar 3, 2026
D Filing Feb 26, 2026 —
6-K Current report (foreign issuer) Feb 25, 2026 Feb 25, 2026
6-K Current report (foreign issuer) Feb 20, 2026 Feb 20, 2026
6-K Current report (foreign issuer) Feb 19, 2026 Feb 19, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 17, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 13, 2026 —
6-K Current report (foreign issuer) Feb 10, 2026 Feb 10, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Feb 10, 2026 —
SCHEDULE 13D/A Amended ownership over 5% (active) Jan 29, 2026 —
D Filing Jan 28, 2026 —
D Filing Jan 28, 2026 —
6-K Current report (foreign issuer) Jan 22, 2026 Jan 22, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Jan 20, 2026 —
SCHEDULE 13D/A Amended ownership over 5% (active) Jan 20, 2026 —
6-K Current report (foreign issuer) Jan 13, 2026 Jan 13, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Jan 9, 2026 —
6-K Current report (foreign issuer) Dec 31, 2025 Dec 30, 2025
6-K Current report (foreign issuer) Dec 23, 2025 Dec 23, 2025
SCHEDULE 13D/A Amended ownership over 5% (active) Dec 18, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Dec 17, 2025 —
6-K Current report (foreign issuer) Dec 11, 2025 Dec 11, 2025
SCHEDULE 13G Ownership over 5% (passive) Nov 26, 2025 —
6-K Current report (foreign issuer) Nov 19, 2025 Nov 19, 2025
6-K Current report (foreign issuer) Nov 14, 2025 Nov 14, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
6-K Current report (foreign issuer) Nov 10, 2025 Nov 10, 2025
SCHEDULE 13D Ownership over 5% (active) Sep 26, 2025 —
6-K Current report (foreign issuer) Sep 26, 2025 Sep 26, 2025
6-K Current report (foreign issuer) Sep 2, 2025 Sep 2, 2025
6-K Current report (foreign issuer) Aug 29, 2025 Aug 29, 2025
6-K Current report (foreign issuer) Aug 27, 2025 Aug 27, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 12, 2025 —
6-K Current report (foreign issuer) Aug 4, 2025 Aug 4, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Jul 23, 2025 —
6-K Current report (foreign issuer) Jul 22, 2025 Jul 21, 2025
SCHEDULE 13D/A Amended ownership over 5% (active) Jun 20, 2025 —
6-K Current report (foreign issuer) May 20, 2025 May 20, 2025
6-K/A Form 6-k/a May 20, 2025 May 20, 2025
6-K Current report (foreign issuer) May 16, 2025 May 16, 2025
6-K Current report (foreign issuer) May 14, 2025 May 14, 2025
6-K Current report (foreign issuer) May 12, 2025 May 12, 2025
6-K Current report (foreign issuer) May 7, 2025 May 7, 2025
6-K Current report (foreign issuer) Apr 9, 2025 Apr 9, 2025
6-K Current report (foreign issuer) Apr 3, 2025 Apr 3, 2025
6-K Current report (foreign issuer) Apr 3, 2025 Apr 3, 2025
424B5 Prospectus supplement Apr 1, 2025 —
20-F Annual report (foreign issuer) Mar 31, 2025 Dec 31, 2024
6-K Current report (foreign issuer) Mar 31, 2025 Mar 31, 2025
6-K Current report (foreign issuer) Feb 10, 2025 Feb 10, 2025
SCHEDULE 13D/A Amended ownership over 5% (active) Feb 3, 2025 —
6-K Current report (foreign issuer) Jan 21, 2025 Jan 21, 2025
EFFECT Filing Dec 31, 2024 —
CORRESP Letter to the SEC Dec 30, 2024 —
UPLOAD Letter from the SEC Dec 26, 2024 —
6-K Current report (foreign issuer) Dec 26, 2024 Dec 26, 2024
F-3/A Form f-3/a Dec 23, 2024 —
F-3 Shelf registration (foreign issuer) Dec 20, 2024 —
6-K Current report (foreign issuer) Dec 16, 2024 Dec 16, 2024
6-K Current report (foreign issuer) Nov 15, 2024 Nov 15, 2024
SC 13G/A Amended ownership over 5% (passive) Oct 29, 2024 —
6-K Current report (foreign issuer) Sep 12, 2024 Sep 12, 2024
EFFECT Filing Sep 3, 2024 —
CORRESP Letter to the SEC Aug 29, 2024 —
F-3/A Filing Aug 29, 2024 —
UPLOAD Letter from the SEC Aug 23, 2024 —
F-3 Shelf registration (foreign issuer) Aug 16, 2024 —
6-K Current report (foreign issuer) Aug 16, 2024 Aug 16, 2024
S-8 Employee stock plan registration Aug 14, 2024 —
SC 13D/A Amended ownership over 5% (active) Aug 12, 2024 —
SC 13G Ownership over 5% (passive) Jul 25, 2024 —
6-K Current report (foreign issuer) Jul 19, 2024 Jul 19, 2024
D Filing Jul 15, 2024 —
6-K Current report (foreign issuer) Jul 8, 2024 Jul 8, 2024
6-K Current report (foreign issuer) Jun 27, 2024 Jun 27, 2024
6-K Current report (foreign issuer) Jun 27, 2024 Jun 27, 2024
SC 13G Ownership over 5% (passive) Jun 20, 2024 —
SC 13G/A Amended ownership over 5% (passive) Jun 11, 2024 —
UPLOAD Letter from the SEC Jun 10, 2024 —
CORRESP Letter to the SEC May 30, 2024 —
UPLOAD Letter from the SEC May 22, 2024 —
6-K Current report (foreign issuer) May 15, 2024 May 14, 2024
EFFECT Filing May 10, 2024 —
CORRESP Letter to the SEC May 9, 2024 —
UPLOAD Letter from the SEC May 8, 2024 —
F-3 Shelf registration (foreign issuer) May 3, 2024 —
6-K Current report (foreign issuer) Apr 8, 2024 Apr 8, 2024
6-K Current report (foreign issuer) Mar 28, 2024 Mar 28, 2024
20-F Annual report (foreign issuer) Mar 28, 2024 Dec 31, 2023
144 Notice of proposed sale Mar 15, 2024 —
6-K Current report (foreign issuer) Mar 13, 2024 Mar 13, 2024
144 Notice of proposed sale Mar 5, 2024 —
6-K Current report (foreign issuer) Feb 29, 2024 Feb 29, 2024
6-K Current report (foreign issuer) Feb 12, 2024 Feb 9, 2024
6-K Current report (foreign issuer) Jan 30, 2024 Jan 29, 2024
SC 13G/A Amended ownership over 5% (passive) Jan 26, 2024 —
6-K Current report (foreign issuer) Dec 15, 2023 Dec 15, 2023
6-K Current report (foreign issuer) Dec 8, 2023 Dec 6, 2023
6-K Current report (foreign issuer) Nov 14, 2023 Nov 14, 2023
SC 13G/A Amended ownership over 5% (passive) Nov 9, 2023 —
6-K Current report (foreign issuer) Nov 8, 2023 Nov 8, 2023
UPLOAD Letter from the SEC Sep 19, 2023 —
CORRESP Letter to the SEC Aug 25, 2023 —
UPLOAD Letter from the SEC Aug 14, 2023 —
6-K Current report (foreign issuer) Aug 11, 2023 Aug 11, 2023
6-K Current report (foreign issuer) Aug 1, 2023 Aug 1, 2023
6-K Current report (foreign issuer) Jul 20, 2023 Jul 20, 2023
SC 13G/A Amended ownership over 5% (passive) Jun 23, 2023 —
S-8 POS Form s-8 May 23, 2023 —
S-8 POS Form s-8 May 23, 2023 —
S-8 POS Form s-8 May 23, 2023 —
S-8 POS Form s-8 May 23, 2023 —
6-K Current report (foreign issuer) May 17, 2023 May 17, 2023
6-K Current report (foreign issuer) May 17, 2023 May 17, 2023
6-K Current report (foreign issuer) Apr 26, 2023 Apr 26, 2023
20-F Annual report (foreign issuer) Apr 26, 2023 Dec 31, 2022
6-K Current report (foreign issuer) Apr 26, 2023 Apr 26, 2023
SC 13D/A Amended ownership over 5% (active) Apr 18, 2023 —
SC 13G Ownership over 5% (passive) Apr 10, 2023 —
8-A12B Form 8-a12b Mar 27, 2023 —
S-8 POS Filing Mar 21, 2023 —
S-8 POS Filing Mar 21, 2023 —
S-8 POS Filing Mar 21, 2023 —
S-8 POS Filing Mar 21, 2023 —
6-K Current report (foreign issuer) Mar 21, 2023 Mar 21, 2023
424B3 Prospectus Feb 14, 2023 —
EFFECT Filing Feb 13, 2023 —
CORRESP Letter to the SEC Feb 9, 2023 —
F-4/A Filing Feb 9, 2023 —
UPLOAD Letter from the SEC Feb 8, 2023 —
F-4 Filing Jan 31, 2023 —

Showing 157 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CASIF (OTC)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Beijing, China
SEC filer status
Non-accelerated filer
SEC CIK
1962738
Former names
CASI Pharmaceuticals Holdings, Inc. (until Feb 14, 2023)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.